 |
|
|
| |
C-BREEZE-2: Efficacy and Safety of a Two-Drug Direct-Acting
Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir
450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus
Genotype 1, 2, 3, 4, 5, or 6
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting 2017, October 20-24, 2017, Washington, DC
Eric Lawitz1, Edward Gane2, Jordan J. Feld3, Maria Buti4, Graham R. Foster5, Mordechai Rabinovitz6,
Eduard Burnevich7, Helena Katchman8, Krzysztof Tomasiewicz9, Fred Lahser10, Beth Jackson10,
Melissa Shaughnessy10, Stephanie Klopfer10, Wendy W. Yeh10, Michael Robertson10,
George J. Hanna10, Eliav Barr10, Heather L. Platt10
1Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA;
2Auckland Clinical Studies, Auckland, New Zealand;
3Toronto Centre for Liver Disease, University of Toronto, Toronto, ON, Canada;
4Liver Unit Hospital Universitari Vall d'Hebron
and Centro de Investigación Biomédica en Red de
Enfermedades Hepáticas y Digestivas (CIBERehd) del Instituto Carlos III Barcelona, Barcelona, Spain;
5Queen Mary University, London, UK;
6Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center,
University of Pittsburgh, PA, USA;
7I.M. Sechenov First Moscow State Medical University, Moscow, Russia;
8Department of Gastroenterology,
Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel;
9Medical University of Lublin, Lublin, Poland; 10Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
